论文部分内容阅读
目的 探讨吸入用糖皮质激素布地奈德对伴有吸烟的COPD频繁急性加重表型患者的呼出气一氧化氮水平影响的分析及其临床意义.方法 选取2015年 6-2016年6月于华北理工大学附属医院住院的慢阻肺频繁急性加重表型患者80例,分为吸烟组(观察组)及无吸烟组(对照组),分别经吸入布地奈德有效治疗2周前后测定2组的FENO,分析其FENO 的变化.结果 治疗前吸烟组的FeNO 平均值为 (24.06±9.68) ppb,明显低于无吸烟组的 FeNO 平均值 (29.66±8.22) ppb (P 0.05).结论 吸烟可以降低 COPD频繁急性加重表型患者的呼出气一氧化氮含量,布地奈德可抑制COPD频繁急性加重表型的气道炎症反应,且吸烟还可降低布地奈德对气道炎症反应治疗的敏感性.“,”Objective To investigate the influence of budesonide on FeNO level in smoking AECOPD patients and its clinical significance.Methods 80 AECOPD patients from 2015 6 to June 2016 in North China Polytechnic University Hospital were divided into the smoking group (the observation group) and the no smoking group (the control group).They were all treated with budesonide inhalation, and the levels of FeNO were measured 2 weeks before and after treatment.Results Before treatment, the average FeNO value was (24.06±9.68) ppb in the smoking group, significantly lower than (29.66±8.22) in the non-smoking group (P 0.05).Conclusion Smoking can reduce the level of FeNO in AECOPD, and budesonide can inhibit their airway inflammation, and smoking can reduce the sensitivity of budesonide on airway inflammation treatment.